In recent years, much attention has been focused on cyclosporin as a new alternative drug for the treatment of recalcitrant disabling psoriasis vulgaris. This drug has the important advantage of being non-myelotoxic as compared to other immunosuppressants. In conjunction with the earlier reported data concerning the clinical use of cyclosporin to treat severe psoriasis, three treatment schedules are outlined: short-term, intermittent and long-term. Uncontrolled treatment of psoriasis with cyclosporin could increase the risk of irreversible renal damage. The use of cyclosporin, therefore, requires a multidisciplinary ap proach in which regular consultations and monitoring by a dermatologist and, if warranted, by a nephrologist are imperative.